Full text

Turn on search term navigation

© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Topical delivery has received great attention due to its localized drug delivery, its patient compliance, and its low risk for side effects. Recent developments have focused on studying new drug delivery systems as a strategy for addressing the challenges of current topical treatments. Here we describe the advances on an innovative drug delivery platform called DELOS nanovesicles for topical drug delivery. Previously, the production of DELOS nanovesicles demonstrated potentiality for the topical treatment of complex wounds, achieving well-tolerated liquid dispersions by this route. Here, research efforts have been focused on designing these nanocarriers with the best skin tolerability to be applied even to damaged skin, and on exploring the feasibility of adapting the colloidal dispersions to a more suitable dosage form for topical application. Accordingly, these drug delivery systems have been efficiently evolved to a hydrogel using MethocelTM K4M, presenting proper stability and rheological properties. Further, the integrity of these nanocarriers when being gellified has been confirmed by cryo-transmission electron microscopy and by Förster resonance energy transfer analysis with fluorescent-labeled DELOS nanovesicles, which is a crucial characterization not widely reported in the literature. Additionally, in vitro experiments have shown that recombinant human Epidermal Growth Factor (rhEGF) protein integrated into gellified DELOS nanovesicles exhibits an enhanced bioactivity compared to the liquid form. Therefore, these studies suggest that such a drug delivery system is maintained unaltered when hydrogellified, becoming the DELOS nanovesicles-based hydrogels, an advanced formulation for topical use.

Details

Title
DELOS Nanovesicles-Based Hydrogels: An Advanced Formulation for Topical Use
Author
Ballell-Hosa, Lídia 1 ; González-Mira, Elisabet 2 ; Santana, Hector 3   VIAFID ORCID Logo  ; Morla-Folch, Judit 2   VIAFID ORCID Logo  ; Moreno-Masip, Marc 4 ; Martínez-Prieto, Yaima 3 ; Revuelta, Albert 4 ; Primiano Pio Di Mauro 2 ; Veciana, Jaume 2   VIAFID ORCID Logo  ; Sala, Santi 5 ; Ferrer-Tasies, Lidia 5   VIAFID ORCID Logo  ; Ventosa, Nora 2   VIAFID ORCID Logo 

 Nanomol Technologies S.L., 08193 Cerdanyola del Vallès, Spain; [email protected] (L.B.-H.); [email protected] (S.S.); Institut de Ciència de Materials de Barcelona (ICMAB-CSIC), 08193 Bellaterra, Spain; [email protected] (E.G.-M.); [email protected] (J.M.-F.); [email protected] (M.M.-M.); [email protected] (A.R.); [email protected] (P.P.D.M.); [email protected] (J.V.); Centro de Investigación Biomédica en Red-Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), 28029 Madrid, Spain 
 Institut de Ciència de Materials de Barcelona (ICMAB-CSIC), 08193 Bellaterra, Spain; [email protected] (E.G.-M.); [email protected] (J.M.-F.); [email protected] (M.M.-M.); [email protected] (A.R.); [email protected] (P.P.D.M.); [email protected] (J.V.); Centro de Investigación Biomédica en Red-Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), 28029 Madrid, Spain 
 Center for Genetic Engineering and Biotechnology (CIGB), 31st Avenue between 158 and 190 Streets, Cubanacán, Playa, Havana 10600, Cuba; [email protected] (H.S.); [email protected] (Y.M.-P.) 
 Institut de Ciència de Materials de Barcelona (ICMAB-CSIC), 08193 Bellaterra, Spain; [email protected] (E.G.-M.); [email protected] (J.M.-F.); [email protected] (M.M.-M.); [email protected] (A.R.); [email protected] (P.P.D.M.); [email protected] (J.V.) 
 Nanomol Technologies S.L., 08193 Cerdanyola del Vallès, Spain; [email protected] (L.B.-H.); [email protected] (S.S.) 
First page
199
Publication year
2022
Publication date
2022
Publisher
MDPI AG
e-ISSN
19994923
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2621365154
Copyright
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.